Bronchial hyperresponsiveness, airway inflammation, and reversibility in patients with chronic obstructive pulmonary disease

International Journal of COPD

Volumn 10, Issue , 2015, Pages 1155-1161

  Zanini, Andrea ^a   Cherubino, Francesca ^a   Zampogna, Elisabetta ^a   Croce, Stefania ^a   Pignatti, Patrizia ^a   Spanevello, Antonio ^b  

^a IRCCS   (Italy)

^b UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

COPD; Exacerbations; Hyperreactivity; Methacholine; Sputum eosinophilia

Indexed keywords

METHACHOLINE; BRONCHODILATING AGENT;

AGED; ARTICLE; BRONCHIAL HYPERRESPONSIVENESS; BRONCHIAL REVERSIBILITY; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; EOSINOPHIL; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INHALATION TEST; LUNG FUNCTION; MALE; OUTCOME ASSESSMENT; RESPIRATORY TRACT ALLERGY; RESPIRATORY TRACT INFLAMMATION; RESPIRATORY TRACT PARAMETERS; SCORING SYSTEM; SPUTUM ANALYSIS; SYNDROME DELINEATION; BRONCHIAL HYPERREACTIVITY; CROSS-SECTIONAL STUDY; CYTOLOGY; DISEASE COURSE; DRUG EFFECTS; IMMUNOLOGY; LUNG; MIDDLE AGED; PATHOPHYSIOLOGY; PNEUMONIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EOSINOPHILIA; SEVERITY OF ILLNESS INDEX; SPIROMETRY; SPUTUM; TIME FACTOR; TREATMENT OUTCOME; VITAL CAPACITY;

AGED; BRONCHIAL HYPERREACTIVITY; BRONCHIAL PROVOCATION TESTS; BRONCHODILATOR AGENTS; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; MALE; MIDDLE AGED; PNEUMONIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EOSINOPHILIA; SEVERITY OF ILLNESS INDEX; SPIROMETRY; SPUTUM; TIME FACTORS; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84933533134     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S80992     Document Type: Article

References (43)

1. Schwartz J, Schindler C, Zemp E, et al. Predictors of methacholine responsiveness in a general population. Chest. 2002;122(3):812-820.
2. Brutsche MH, Downs SH, Schindler C, et al; SAPALDIA Team. Bronchial hyperresponsiveness and the development of asthma and COPD in asymptomatic individuals: SAPALDIA cohort study. Thorax. 2006;61(8):671-677.
3. Magnussen H, Nowak D. Roles of hyperresponsiveness and airway inflammation in bronchial asthma. Respiration. 1989;55(2):65-74.
4. Crimi E, Spanevello A, Neri M, Ind PW, Rossi GA, Brusasco V. Dissociation between airway inflammation and airway hyperresponsiveness in allergic asthma. Am J Respir Crit Care Med. 1998;157(1):4-9.
5. Chinn S, Jarvis D, Luczynska CM, et al. An increase in bronchial responsiveness is associated with continuing or restarting smoking. Am J Respir Crit Care Med. 2005;172(8):156-161.
6. Wise RA, Kanner RE, Lindgren P, et al; Lung Health Study Research Group. The effect of smoking intervention and an inhaled bronchodilator on airways reactivity in COPD: the Lung Health Study. Chest. 2003;124(2):449-458.
7. Tashkin DP, Altose MD, Bleecker ER, et al. The lung health study: airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation. The Lung Health Study Research Group. Am Rev Respir Dis. 1992;145(2 Pt 1):301-310.
8. van den Berge M, Vonk JM, Gosman M, et al. Clinical and inflammatory determinants of bronchial hyperresponsiveness in COPD. Eur Respir J. 2012;40(5):1098-1105.
9. Ronchi MC, Piragino C, Rosi E, Amendola M, Duranti R, Scano G. Role of sputum differential cell count in detecting airway inflammation in patients with chronic bronchial asthma or COPD. Thorax. 1996;51(10):1000-1004.
10. Saetta M, Di Stefano A, Turato G, et al. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(3 Pt 1):822-826.
11. Brightling CE, Monteiro W, Ward R, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomized controlled trial. Lancet. 2000;356(9240):1480-1485.
12. Siva R, Green RH, Brightling CE, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomized controlled trial. Eur Respir J. 2007;29(5):906-913.
13. Calverley PM, Burge PS, Spencer S, Anderson JA, Jones PW; for the ISOLDE Study Investigators. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax. 2003;58(8):659-664.
14. Papi A, Romagnoli M, Baraldo S, et al. Partial reversibility of airflow obstruction and increased NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;162(5):1773-1777.
15. Dima E, Rovina N, Gerassimou C, Roussos C, Gratziou C. Pulmonary function tests, sputum induction, and bronchial provocation tests: diagnostic tools in the challenge of distinguishing asthma and COPD phenotypes in clinical practice. Int J Chron Obstruct Pulmon Dis. 2010;5:287-296.
16. Carolan BJ, Sutherland ER. Clinical phenotypes of chronic obstructive pulmonary disease and asthma: recent advances. J Allergy Clin Immunol. 2013;131(3):627-634.
17. Burgel PR, Paillasseur JL, Caillaud D, et al; Initiatives BPCO Scientific Committee. Clinical COPD phenotypes: a novel approach using principal component and cluster analyses. Eur Respir J. 2010;36(3):531-539.
18. Nishimura M, Makita H, Nagai K, et al; Hokkaido COPD Cohort Study Investigators. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185(1):44-52.
19. Izquierdo-Alonso JL, Rodriguez-Gonzálezmoro JM, de Lucas-Ramos P, et al. Prevalence and characteristics of three clinical phenotypes of chronic obstructive pulmonary disease (COPD). Respir Med. 2013;107(5):724-731.
20. Garcia-Aymerich J, Gómez FP, Benet M, et al; PAC-COPD Study Group. Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax. 2011;66(5):430-437.
21. Hardaker KM, Downie SR, Kermode JA, Berend N, King GG, Salome CM. Ventilation heterogeneity is associated with airway responsiveness in asthma but not COPD. Respir Physiol Neurobiol. 2013;189(1):106-111.
22. Vestbo J, Hurd SS, Agustì AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347-365.
23. Beier J, Kirsten A-M, Mróz R, et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study. COPD. 2013;10(4):511-522.
24. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26(5):948-968.
25. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993;16:5-40.
26. Cotes JE, Chinn DJ, Quanjer PH, Roca J, Yernault JC. Standardization of the measurement of transfer factor (diffusing capacity). Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993;16:41-52.
27. Sterk PJ, Fabbri LM, Quanjer PH, et al. Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Eur Respir J. 1993;6(Suppl 16):53s-83s.
28. Pignatti P, Zanini A, Della Patrona S, Gumiero F, Cherubino F, Spanevello A. Pulmonary function testing: sputum and exhaled breath analysis. In: Palange P, Simonds AK, editors. ERS Handbook of Respiratory Medicine. 2nd ed. Sheffield, UK: European Respiratory Society; 2013:103-108.
29. European Respiratory Task Force. Standardised methodology of sputum induction and processing. Eur Respir J. 2002;20(Suppl 37):1s-55s.
30. Yan K, Salome CM, Woolcock AJ. Prevalence and nature of bronchial hyperresponsiveness in subjects with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1985;132(1):25-29.
31. Tashkin DP, Altose MD, Connett JE, Kanner RE, Lee WW, Wise RA. Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group. Am J Respir Crit Care Med. 1996;153(6 Pt 1):1802-1811.
32. Postma DS, Kerstjens HA. Characteristics of airway hyperresponsiveness in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;158(5 Pt 3):S187-S192.
33. Hospers JJ, Postma DS, Rijcken B, Weiss ST, Schouten JP. Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study. Lancet. 2000;356(9238):1313-1317.
34. Lapperre TS, Snoeck-Stroband JB, Gosman MM, et al; Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease Study Group. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2009;151(8):517-527.
35. de Nijs SB, Fens N, Lutter R, et al. Airway inflammation and mannitol challenge test in COPD. Respir Res. 2011;12:11.
36. Rutgers SR, Timens W, Tzanakis N, et al. Airway inflammation and hyperresponsiveness to adenosine 5-monophosphate in chronic obstructive pulmonary disease. Clin Exp Allergy. 2000;30(5):657-662.
37. Lapperre TS, Snoeck-Stroband JB, Gosman MM, et al; Groningen and Leiden Universities Corticosteroids in Obstructive Lung Disease Study Group. Dissociation of lung function and airway inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;170(5):499-504.
38. Scichilone N, Battaglia S, La Sala A, Bellia V. Clinical implications of airway hyperresponsiveness in COPD. Int J Chron Obstruct Pulmon Dis. 2006;1(1):49-60.
39. Jeffery PK. Pathology of asthma and COPD: a synopsis. Eur Respir Rev. 1997;7:111-118.
40. Saetta M. Central airways inflammation in the development of COPD. Eur Respir Rev. 1997;7:109-110.
41. van Veen IH, Ten Brinke A, Gauw SA, Sterk PJ, Rabe KF, Bel EH. Consistency of sputum eosinophilia in difficult-to-treat asthma: a 5-year follow-up study. J Allergy Clin Immunol. 2009;124(3):615-617.
42. Simpson JL, McElduff P, Gibson PG. Assessment and reproducibility of non-eosinophilic asthma using induced sputum. Respiration. 2010;79(2):147-151.
43. Albert P, Agusti A, Edwards L, et al. Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax. 2012;67(8):701-708.